Overview of Dr. Friedlander
Dr. Philip Friedlander is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, and Valley Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 18 years. Dr. Friedlander accepts several types of health insurance, listed below. He is one of 189 doctors at The Mount Sinai Hospital and one of 123 doctors at Mount Sinai Beth Israel who specialize in Oncology. He has more than 30 publications and over 500 citings.
Office
1 Gustave L Levy Pl
New York, NY 10029Fax+1 212-731-5210
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
- FL State Medical License 2020 - Present
- NJ State Medical License 2017 - 2025
- NY State Medical License 2000 - 2025
- MA State Medical License 2005 - 2012
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
- The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Start of enrollment: 2013 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 442 citationsBevacizumab plus Ipilimumab in Patients with Metastatic MelanomaF. Stephen Hodi, Donald P. Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou
Cancer Immunology Research. 2014-07-01 - 148 citationsFinal Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Pat...Steven J. O'Day, Alexander M.M. Eggermont, Vanna Chiarion-Sileni, Richard F. Kefford, Jean-Jacques Grob
Journal of Clinical Oncology. 2013-03-20 - 45 citationsHematological immune related adverse events after treatment with immune checkpoint inhibitors.Rafaela Kramer, Anne Zaremba, Alvaro Moreira, Selma Ugurel, Douglas B. Johnson
European Journal of Cancer. 2021-03-09
Press Mentions
- Experts Agree Sun Exposure Is a Cancer RiskSeptember 7th, 2022
- Immune-Boosting Components Double the Effectiveness of Melanoma Vaccine Candidate in Phase II TrialNovember 17th, 2020
- 'Truly Amazing': Huge Change in Melanoma PrognosisOctober 26th, 2019
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS California PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
Health Net California Large Group PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: